Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Beijing
Clinical trial register · China

Clinical Trials in Beijing, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19187 matching records held by the registry are in this view. Synced 07 Nov 2026, 03:17 UTC
19187
Studies in scope
all four open statuses
11790
Recruiting now
open to new participants
2028
Lead sponsors
across recruiting studies
Top sites
Guangzhou 44 Beijing 38 Shanghai 26 Fuzhou 20 Hangzhou 18
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca7 Sun Yat-sen University6 Chinese PLA General Hospital4 Peking Union Medical College Hospital3 Cancer Institute and Hospital, Chinese Academy of Medical Sciences2
Site location
Guangzhou44 Beijing38 Shanghai26 Fuzhou20 Hangzhou18
All 57 locations
Target enrolment
to

Trials with a site in Beijing

38 of 19187 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
West China Hospital
Not applicable
60
Beijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Nanjing, Shanghai
2026-12-01
Recruiting
68Ga-SorB PET/CT Imaging in Patients With Solid Tumors
NCT07760012Melanoma (Skin Cancer), Hepatocellular Carcinoma, Lung Cancer, Breast Cancer
Peking University Third Hospital
Not applicable
50
Beijing
2026-08-13
Recruiting
Beijing Municipal Administration of Hospitals
Observational
40
Beijing
2026-06-30
Recruiting
Lepu Biopharma Co., Ltd.
Phase 1/2
160
Beijing, Fuzhou, Zhengzhou, Nanjing, Tianjin, Lishui
2026-04-08
Recruiting
Peking Union Medical College Hospital
Phase 2
158
Beijing, Nanjing, Xuzhou
2025-12-24
Active, closed
AstraZeneca
Phase 2
114
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Hefei, Jinan, Nanjing
2025-08-05
Recruiting
Chinese PLA General Hospital
Phase 1
25
Beijing
2025-06-20
Recruiting
Shanghai Junshi Bioscience Co., Ltd.
Phase 2
72
Hefei, Beijing, Harbin, Zhengzhou, Changsha, Nanchang, Shenyang, Shanghai
2025-05-29
Recruiting
AstraZeneca
Phase 3
1,220
Beijing, Changchun, Changsha, Chengdu, Chifeng, Chongqing, Deyang, Fuzhou
2025-05-06
Not yet open
Chinese PLA General Hospital
Observational
300
Beijing
2025-01-30
Recruiting
TACE Combined Surgery for the Resectable Huge HCC
NCT06898398Hepatocellular Carcinoma, Hepatic Chemotherapy, Liver Cancer, Surgery
Sun Yat-sen University
Observational
326
Beijing
2025-01-01
Recruiting
TACE Combined With Lenvatinib and PD-1 Inhibitor for Ruptured Hepatocellular Carcinoma
NCT06740370Hepatocellular Carcinoma, Transcatheter Arterial Chemoembolization, Anti-PD1 Antibody, Lenvatinib
DrugsVenetocalx·Lenvatinib
Sun Yat-sen University
Not applicable
32
Beijing
2024-12-13
Recruiting
HAIC Compared With TACE in Huge Hepatocellular Carcinoma
NCT06641713Hepatocellular Carcinoma, Hepatic Chemotherapy, Liver Cancer
Sun Yat-sen University
Observational
664
Beijing
2024-10-01
Recruiting
TIPS Combined With Lenvatinib and PD-1 Inhibitor for Advanced HCC With Main Trunk PVTT
NCT06622031Hepatocellular Carcinoma, Portal Vein Tumor Thrombus, Systemic Therapy
DrugLenvatinib
Sun Yat-sen University
Not applicable
42
Beijing
2024-10-01
Recruiting
Donafenib as Adjuvant Therapy Following Ablation for Recurrent HCC
NCT06609876Hepatocellular Carcinoma, Microwave Ablation, Donafenib, Recurrent Tumor
DrugDonafenib
Sun Yat-sen University
Not applicable
108
Beijing
2024-10-01
Recruiting
Akeso
Phase 1/2
280
Beijing, Jinan
2024-09-24
Recruiting
Lion TCR Pte. Ltd.
Phase 1
10
Beijing
2024-06-01
Recruiting
Phase II Study of Moderate-dose Hypofractionated RT Combined With Pembrolizumab for HCC With Diffuse Tumor Thrombosis
NCT06389422Hepatocellular Carcinoma, Radiotherapy, Pembrolizumab, Tumor Thrombosis
DrugPembrolizumab
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
30
Beijing
2024-05-01
Recruiting
Peking Union Medical College Hospital
Phase 1
40
Beijing
2024-03-11
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
100
Beijing
2024-01-26
Recruiting
Zhongda Hospital
Not applicable
188
Beijing, Nanjing
2023-12-19
Active, closed
Hoffmann-La Roche
Phase 3
687
Baoji, Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou
2023-09-14
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
480
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Nanning
2023-05-10
Active, closed
AstraZeneca
Phase 2
294
Beijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Harbin, Nanning, Shanghai
2023-04-24
Active, closed
AstraZeneca
Phase 3
214
Beijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan
2023-02-15
Recruiting
Beijing Hospital
Not applicable
88
Beijing
2023-02-01
Recruiting
OriCell Therapeutics Co., Ltd.
Phase 1/2
105
Beijing, Changsha, Changchun, Chengdu, Hangzhou, Lishui, Shanghai
2022-12-15
Active, closed
AstraZeneca
Phase 3
760
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou
2022-03-28
Recruiting
Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
NCT05024214Solid Tumors, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma
DrugsEnvafolimab·Sunitinib·Lenvatinib
3D Medicines (Sichuan) Co., Ltd.
Phase 1/2
170
Bengbu, Beijing, Fuzhou, Xiamen, Dongguan, Guangzhou, Zhuhai, Haerbin
2021-11-15
Active, closed
Hoffmann-La Roche
Phase 3
342
Anhui, Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2021-03-12
Recruiting
HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma
NCT06333561Hepatocellular Carcinoma, Lenvatinib, PD-1 Inhibitor, Hepatic Arterial Infusion Chemotherapy
DrugsCamrelizumab·Toripalimab·Sintilimab·Lenvatinib
Sun Yat-sen University
Observational
300
Beijing
2021-01-01
Active, closed
Peking Union Medical College Hospital
Observational
180
Beijing
2020-12-06
Recruiting
Chinese PLA General Hospital
Not applicable
1,134
Beijing
2019-12-26
Active, closed
CStone Pharmaceuticals
Phase 3
534
Bengbu, Hefei, Beijing, Fuzhou, Xiamen, Foshan, Guangzhou, Nanning
2019-12-13
Active, closed
AstraZeneca
Phase 3
724
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin
2018-11-30
Recruiting
Humanity & Health Medical Group Limited
Observational
5,000
Beijing
2018-07-16
Active, closed
AstraZeneca
Phase 3
1,324
Beijing, Changchun, Changsha, Chengdu, Dalian, Fuzhou, Guangzhou, Hangzhou
2017-10-11
Recruiting
Chinese PLA General Hospital
Phase 2/3
80
Beijing
2009-12
Rows per page Showing 1–38 of 38
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 7 November 2026. https://priyalifescience.com/clinical-trials-china/city/beijing

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,187 studies in total at the last sync on 07 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 38 of those studies with a site in Beijing that also match the filters currently applied.

How many clinical trials are recruiting in Beijing?

26 of the 38 studies on this page are recruiting new participants as of the 07 Nov 2026, 03:17 UTC sync. A further 2 have not yet opened recruitment, 10 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Beijing), 38 studies
PhaseStudiesRecruitingShare
Phase 39223.7%
Not applicable8721.1%
Observational7518.4%
Phase 26415.8%
Phase 1/24410.5%
Phase 1337.9%
Phase 2/3112.6%

Most active sponsors

Lead sponsors with the most studies (Beijing)
Lead sponsorStudiesRecruiting
AstraZeneca71
Sun Yat-sen University66
Chinese PLA General Hospital43
Peking Union Medical College Hospital32
Cancer Institute and Hospital, Chinese Academy of Medical Sciences22
Hoffmann-La Roche20
3D Medicines (Sichuan) Co., Ltd.11
Akeso11
Beijing Hospital11
Beijing Municipal Administration of Hospitals11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.